There have been several updates in the field of prostate cancer over the last several weeks. Here, CURE® looks back at some of the latest news and updates affecting patients with the disease.
- Family history of prostatic borderline or in situ neoplasia (PBSIN) appears to be as important as invasive prostate cancer (PCa) when it comes to increased risk of disease or death. This history should be an essential consideration in screening recommendations for prostate cancer and in research, according to study results published in Cancer.
- While prostate cancer treatment can cause cardiovascular-related side effects, patients can take certain steps to mitigate those risks, according to Dr. Neal D. Shore, medical director of the Carolina Urologic Research Center.
- Black men with newly diagnosed, castration-resistant prostate cancer (mCRPC) that has metastasized to bone do not face an increased risk of skeletal-related events (SREs) or overall mortality, according to recent study findings published in Cancer.
- The risk for a major cardiovascular event was reduced by more than half in patients who received relugolix compared with the hormone-associated therapy leuprolide.
- The Food and Drug Administration (FDA) issued regulatory clarity on the pivotal phase 3 trial design for VERU-111, a novel androgen-blocking agent being evaluated in metastatic castration-resistant prostate cancer.